Evaluation of the effectiveness of dexmedetomidineine sedation of COVID-19 critically ill patients

Evaluation of the effectiveness of dexmedetomidine in sedation of COVID-19 critically ill patients hospitalized in the intensive care unit , A double blind clinical trial

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20110425006280N13

Enrollment

Registered

2021-08-14

Start date

2021-08-23

Completion date

Unknown

Last updated

2021-08-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

The effect of dexmedomedine in COVID-19 patients.. COVID-19,virus identified

Interventions

Intervention 1: Intervention group consists of 30 patients, which will recieve the standard regimen of COVID-19 treatment including ramdisvir, interferen and corticosteroids and supplements in additio

Eligibility

Sex/Gender

All

Age

18 Years to 75 Years

Inclusion criteria

Inclusion criteria: Patients aged 18 to 75 years admitted to the Intensive Care unit clinical diagnosis of respiratory distress and breathing distress Oxygen saturation less than 93% or positive polymerase chain reaction test connected to non-invasive or invasive ventilation requiring sedative administration.

Exclusion criteria

Exclusion criteria: Pregnant patients Known allergies to opioid drugs or dexmedomeidine.

Design outcomes

Primary

Measure	Time frame
Clinical Symptoms of COVID-19. Timepoint: The total time of the study will be done within 15 days at 8-hour intervals. Method of measurement: questionnaire form.	—

Secondary

Measure	Time frame
Relaxation of critically ill patients with 19 ICUs in terms of agitation and delirium. Timepoint: The duration of examination of patients in the ICU is 15 days. This scoring is done for patients at intervals of 8 hours and the average will be evaluated. Method of measurement: During the period of hospitalization, they will be examined for vital signs and intubation. Delirium and agitation will be assessed based on the Richmond Restlessness-Drowsiness Scale (RSAA).This scale is defined in the scoring range between 0-1.According to this scale, agitation includes items: +1 restless, +2 agitated, 3+ very agitated, +4 fighter.In the case of delirium, it is divided into 0 alert and calm, -1 drowsiness, -2 mild sedation, -3 moderate sedation, -4 deep anesthesia, and -5 absence of any awakening.	—

Measure

Time frame

Relaxation of critically ill patients with 19 ICUs in terms of agitation and delirium. Timepoint: The duration of examination of patients in the ICU is 15 days. This scoring is done for patients at intervals of 8 hours and the average will be evaluated. Method of measurement: During the period of hospitalization, they will be examined for vital signs and intubation. Delirium and agitation will be assessed based on the Richmond Restlessness-Drowsiness Scale (RSAA).This scale is defined in the scoring range between 0-1.According to this scale, agitation includes items: +1 restless, +2 agitated, 3+ very agitated, +4 fighter.In the case of delirium, it is divided into 0 alert and calm, -1 drowsiness, -2 mild sedation, -3 moderate sedation, -4 deep anesthesia, and -5 absence of any awakening.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMohammad Haghighi

Guilan University of Medical Sciences

manesthesist@gmail.com+98 13 1322 3970

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026